510(k) Report

FDA applicant

Wallac OY

Turku, FI24 decisions1992–20147 recalls

FDA records 24 decisions for Wallac OY (Turku, FI) from 1992 to 2014: 22 510(k) clearances and 2 De Novo grants. Most are in product codes JLX (Radioimmunoassay, 17-Hydroxyprogesterone) and CGZ (Electrode, Ion-Specific, Chloride). Its devices cite 12 predicates, 5 of them its own earlier devices. 7 recalls are linked to its devices.

FDA’s records also spell it “Wallac, Inc.”.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) refreshed weekly, last Nov 3, 2026

FIG. A — Illustration, clinical chemistry panel, where it files most

How often FDA has decided Wallac OY’s devices, and how often a recall has named them.

FDA decisions per year

1in 2014

2008: 22009: 12010: 12013: 12014: 1
2007high 2 (2008) · low 0 (2007)2026

2026 so far, outlined.

Recalls per year

1in 2017

2012: 32016: 32017: 1
2007high 3 (2012) · low 0 (2007)2026

Class I Class II/III not classified

FIG. 1 — Wallac OY by year, 2007–2026Sources: FDA decision databases, recall and enforcement reports · Data through Oct 25, 2026

Planning a device like Wallac OY’s? A 510(k) Report ranks candidate predicates for your device by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report

Other applicant names beginning “Wallac”

FDA records each applicant name separately; these may or may not be the same firm.